Replimune Group, Inc.
RP1
melanoma
Countdown
27days
FDA decision · Aug 2, 2026
What's at stake
The FDA's approval decision on RP1 for melanoma is due Aug 2, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“The FDA considers this a complete, class 1 response with a goal date of August 2, 2026, and has notified the company to expect an advisory committee meeting in late July.”